US Broker Ratings

Teva Pharmaceutical Industries (TEVA) Stock Analysis: Potential Upside of 22.82% Signals Strong Growth Prospects

Teva Pharmaceutical Industries (NYSE: TEVA), a stalwart in the global healthcare sector, presents a compelling opportunity for investors with its promising growth potential. The company, headquartered in Israel, is a..

Stevanato Group S.p.A. (STVN) Stock Analysis: Unpacking a 65% Potential Upside

Investors eyeing opportunities in the healthcare sector might find Stevanato Group S.p.A. (NYSE: STVN) an intriguing prospect. Headquartered in Piombino Dese, Italy, Stevanato operates at the cutting edge of the..

Teleflex Incorporated (TFX) Stock Analysis: A Healthcare Innovator with a 17.57% Potential Upside

Teleflex Incorporated (TFX), a dominant player in the medical instruments and supplies industry, continues to showcase its prowess with a diverse range of innovative medical devices. Based in Wayne, Pennsylvania,..

Elevance Health, Inc. (ELV) Stock Analysis: Exploring a 33.91% Potential Upside for Investors

Elevance Health, Inc. (NYSE: ELV), a prominent player in the healthcare sector, stands as a beacon of stability and growth potential for investors looking to capitalize on the robust dynamics..

Qiagen N.V. (QGEN) Stock Analysis: Understanding Its 23.98% Potential Upside

Investors keeping an eye on the healthcare sector, particularly in diagnostics and research, may find Qiagen N.V. (NYSE: QGEN) an intriguing prospect. With a market capitalization of $9.18 billion, Qiagen..

Johnson & Johnson (JNJ) Stock Analysis: Navigating a Healthcare Titan Amidst a -1.29% Potential Downside

As Johnson & Johnson (NYSE: JNJ) continues to solidify its reputation as a leader in the healthcare sector, investors are keenly evaluating its current and future performance metrics. With a..

Grifols, S.A. (GRFS) Investor Outlook: Exploring a 29% Potential Upside Amidst Strategic Growth

Grifols, S.A. (GRFS), a leading player in the healthcare sector with a specialization in plasma-derived medicines, offers an intriguing opportunity for investors seeking exposure to the drug manufacturing industry. Headquartered..

Revolution Medicines, Inc. (RVMD) Stock Analysis: Capitalizing on a 31.45% Potential Upside in Precision Oncology

Revolution Medicines, Inc. (NASDAQ: RVMD) is emerging as a significant player in the biotechnology sector, particularly in the field of precision oncology. With a focus on developing novel targeted therapies..

Encompass Health Corporation (EHC)

⚠️ No article content returned.

..

Pfizer Inc. (PFE) Stock Analysis: Navigating Opportunities Amid a 6.36% Dividend Yield

Pfizer Inc. (NYSE: PFE), the New York-based pharmaceutical giant, commands a prominent position in the healthcare sector with a market capitalization of $153.81 billion. Despite the broad challenges facing the..

West Pharmaceutical Services, Inc. (WST) Stock Analysis: Unlocking a Potential 29.49% Upside

West Pharmaceutical Services, Inc. (NYSE: WST), a key player in the healthcare sector, particularly within the medical instruments and supplies industry, presents a compelling investment opportunity for those seeking growth..

Henry Schein, Inc. (HSIC) Investor Outlook: Explore a 15.7% Upside Potential

Henry Schein, Inc. (NASDAQ: HSIC), a titan in the healthcare sector specializing in medical distribution, stands out with a notable market capitalization of $9.14 billion. Despite a slight dip in..

GSK plc (GSK) Stock Analysis: Exploring a 5.44% Potential Upside in the Healthcare Sector

GSK plc (NYSE: GSK), a titan in the healthcare sector, continues to be a focal point for investors due to its robust product pipeline and global footprint. With a market..

Natera, Inc. (NTRA) Stock Analysis: Why this Diagnostics Leader Offers a Potential 31.56% Upside

Natera, Inc. (NASDAQ: NTRA) stands out in the healthcare sector as a robust player in the diagnostics and research industry. With a market capitalization of $28.08 billion, the company has..

Genmab A/S (GMAB) Stock Analysis: Exploring a 39% Potential Upside for Biotechnology Investors

As a pioneering force in the biotechnology sector, Genmab A/S (GMAB) stands out not only for its innovative antibody-based therapies but also for its compelling investment prospects. Based in Denmark,..

Corcept Therapeutics (CORT) Investor Outlook: Unpacking the 93% Potential Upside

Corcept Therapeutics Incorporated (CORT), a biopharmaceutical company based in Redwood City, California, is capturing investor attention with a compelling story of innovation and potential growth within the healthcare sector. Known..

McKesson Corporation (MCK) Stock Analysis: Healthcare Giant with a Robust Growth Trajectory

As one of the stalwarts in the healthcare sector, McKesson Corporation (NYSE: MCK) continues to stand out in the medical distribution industry. With a market capitalization of $113.46 billion, McKesson..

Neurocrine Biosciences, Inc. (NBIX) Investor Outlook: Exploring a 38% Potential Upside Amid Strong Revenue Growth

Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a prominent player in the healthcare sector, continues to draw investor attention with its compelling financial metrics and robust product pipeline. Specializing in the discovery..

Globus Medical, Inc. (GMED) Stock Analysis: Exploring a 25.76% Potential Upside

Globus Medical, Inc. (NYSE: GMED), a leading player in the healthcare sector, particularly within the medical devices industry, continues to capture investor attention with its innovative solutions for musculoskeletal disorders...

Amgen Inc. (AMGN) Stock Analysis: Evaluating a Solid Player in the Healthcare Sector with Robust Dividend Yield

Amgen Inc. (NASDAQ: AMGN), a stalwart in the healthcare sector, has long been a reliable choice for investors seeking exposure to the pharmaceutical industry. With a market capitalization of $199.2..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds